Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapyPAP · pulmonary arterial hypertension1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 387 participantsHigh
Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERAPAP · pulmonary arterial hypertension1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 11 participantsLow
Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placeboPAP · pulmonary arterial hypertension1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted6 studies · 453 participantsModerate
Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placeboPAP · people with pulmonary hypertension due to lung disease1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 61 participantsModerate
Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placeboPAP · people with pulmonary hypertension due to left‐heart disease1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 130 participantsModerate
Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placeboPAP · people with pulmonary hypertension due to CTEPH2 findings from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 19 participantsLowPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 227 participantsModerate